MyFiziq teams up with leading UK health communications group

|

Published 08-OCT-2020 09:48 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

MyFiziq Limited (ASX: MYQ) has signed a binding term sheet with Jayex Healthcare Limited (ASX: JHL), a UK based health communication monitoring and management technology company.

The Jayex brand is synonymous with patient management systems for general practitioners (GPs) in the UK where the company has been operating for 40 years.

Similar to MyFiziq, Jayex’s shares have been on a tear lately, having increased nearly 80% in the last fortnight with the share price surge supported by the largest trading volumes in more than two years.

Jayex Connect, a platform owned by Jayex, has evolved to become the first all-in-one patient engagement platform, improving the patient experience and the efficiency and productivity of GP practices and hospitals.

The group’s comprehensive suite of communication tools include digital display systems, online appointment booking, SMS and email campaign management, patient self-check-in and mobile check-in, surveys and patient calling.

Jayex, has confirmed its customer base spans 3,250 locations in the UK, Australia and New Zealand, with over 50 million patient interactions per year.

Jayex is entering a new phase of growth following its transition to a SaaS model, and management is adding innovations and functionality to its platform to enhance the value it delivers to GPs and healthcare providers, while increasing market share and revenue per user.

Under the agreement, Jayex intends to integrate the MyFiziq CompleteScan capabilities into its Jayex Connect platform and add new capabilities that allow for remote patient assessment using the CompleteScan platform to assess patient and consumer needs.

Aligns with UK NHS mandate

The partnership is a move into deeper telehealth initiatives being driven by the UK government funded National Health Service (NHS), which recently stated “all patients will have the right to digital consultation by April 2021”.

Under the terms of the binding sheet, Jayex is targeting a minimum of 1,000,000 active users within the first 12 months, but there is no guarantee this number will be achieved.

The parties have agreed to conclude all formal agreements within 120 days of signing the binding term sheet.

MyFiziq does not expect any immediate material financial return as a result of entering into this agreement, but management anticipates the generation of licence and other fees from the commercial arrangement in the future.

The agreement is for a one-year period, and this term shall be renewed for consecutive further terms of 2 years each unless terminated at least 30 days prior to expiry of the term.

Scalability drives down cost per user

There are strong incentives for Jayex to maximise the quantum of active users as the CompleteScan pricing decreases from US$5.49 per month per user for up to 50,000 active users to US$1.80 per month per user for more than 1.5 million users.

MyFiziq chief executive Vlado Bosanac underlined Jayex’s high profile management and well-credentialled brand in saying, “Jayex will be a great partner for MyFiziq.

‘’I have a long history of working with Michael Boyd, who was one of the founding directors’ of Sonic Healthcare (ASX: SHL), a great Australian success story.

‘’Jayex is a highly trusted healthcare brand, and this mutually beneficial partnership gives us access to over 3,250 medical facilities and a platform that boasts impressive 50 million-plus patient engagements per annum.

‘’It creates an opportunity to empower consumers and GPs to add a new dimension to their interactions, and ultimately improve the interaction and patient care.

‘’While we have allowed 120 days to complete the contractual arrangements, both companies are keen to expedite the development and work towards an integrated product release on the Jayex platform.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X